The drug was judged to offer an indication of major additional benefit in adult patients with advanc...
Read moreUnder ODAP, a protocol is drawn up “with criteria for starting, stopping and effect of a medicine....
Read moreThe Access Consortium is made up of regulatory authorities including the UK, Australia, Canada, Sing...
Read moreThe High Authority for Health (HAS) and National Agency for Drug Safety (ANSM) have published a prel...
Read moreWith respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...
Read moreDurvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...
Read moreThe research looks at the benefits for 13 medicines across four treatment areas.
Read moreThe EHDS will integrate three main product markets for primary use of health data: electronic health...
Read moreThe data is derived from the Organisation for Economic Co-operation and Development (OECD) Health St...
Read moreSpending by the main health insurance fund (Caisse nationale d’assurance maladie, CNAM) on medicin...
Read more